Patients in the trial arm (n = 12) experienced grade 3 or higher toxicities such as neutropenia (n = 4, 33.3%), pancreatitis (n = 1, 8.3%), elevated ALT (n = 3, 25%). The gene discussed is GPT; the disease is Decreased total neutrophil count.